Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 8/20 | 0.42 |
| ▸ | MMP3 | P08254 | 6/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7046360 | 0.95 | MMP8 (0.52) | MMP8MMEMMP2MMP3MMP1 | |
| SCHEMBL7052597 | 0.89 | MME (0.54) | MMP8MMEMMP2MMP7MMP12 | |
| SCHEMBL7046985 | 0.87 | MMP1 (0.45) | MMP8MMEMMP3MMP1MMP7 | |
| SCHEMBL6417550 | 0.87 | MMP7 (0.53) | MMP8MMEMMP2MMP3MMP1 | |
| SCHEMBL7050174 | 0.87 | MMP7 (0.53) | MMP8MMEMMP2MMP3MMP1 | |
| SCHEMBL7047135 | 0.83 | MMP8 (0.49) | MMP8MMEMMP2MMP3MMP1 | |
| SCHEMBL7051257 | 0.82 | MMP2 (0.49) | MMP8MMP2MMP3MMP1MMP12 | |
| SCHEMBL7052628 | 0.80 | MMP8 (0.44) | MMP8MMEMMP3MMP1MMP7 | |
| SCHEMBL7049625 | 0.79 | MMP1 (0.42) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL7048194 | 0.79 | MMP7 (0.46) | MMP8MMEMMP2MMP3MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | MMP8 21/4885MME 81/4885MMP2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.